2026年开年以来，随着创新成果的商业化落地及全球化运营的深入，复星国际核心主业延续了此前 强劲的增长势头，在文旅、消费、创新药等赛道迎来新突破。 文旅消费作为复星的核心主业之一，马年春节期间多条产品线展现了出强劲的增长势头。其中，上 海豫园商城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全 包"度假村春节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿 元，同比增长20%，创下历史最佳春节表现。 与此同时，春节期间，复星的创新药赛道也好消息不断。旗下的生物医药研发平台复宏汉霖宣布其 研发的HLX15-SC（重组抗CD38全人单克隆抗体注射液-皮下注射）1期临床试验申请分别获中国国家药 监局批准和美国食品药品管理局（FDA）批准。据了解，HLX15是达雷妥尤单抗生物类似药，目标市 场潜力较大，2024年全球销售额约128.8亿美元。而在2月22日，中国首个自主研发的利妥昔单抗生物类 似药——汉利康迎来上市七周年，该药曾一举填补了国产CD20单抗的空白，作为复星医药"十年磨一 剑"的成果，其标志着中国生物药研发迈出了从跟随到并跑的关键 ...

Core Insights - Fosun International has continued its strong growth momentum in 2026, particularly in sectors such as cultural tourism, consumer goods, and innovative pharmaceuticals, driven by the commercialization of innovative results and deepening global operations [1][2] Group 1: Cultural Tourism and Consumer Growth - During the Spring Festival, Fosun's cultural tourism segment showed robust growth, with Shanghai Yuyuan Mall receiving nearly 1.2 million visitors, a year-on-year increase of over 20% [1] - Club Med's five domestic resorts achieved an average occupancy rate of 90% during the Spring Festival core holiday period [1] - Atlantis Sanya reported a total revenue of 124 million yuan during the Spring Festival holiday, marking a 20% year-on-year growth and setting a record for the best performance during the Spring Festival [1] Group 2: Innovative Pharmaceuticals - Fosun's innovative pharmaceutical sector has seen significant advancements, with its subsidiary, Fuhong Hanlin, receiving clinical trial approvals for HLX15-SC from both the Chinese National Medical Products Administration and the FDA [2] - HLX15, a biosimilar to Daratumumab, has a projected global sales potential of approximately 12.88 billion yuan in 2024 [2] - In 2025, Fosun Pharma's innovative drug revenue exceeded 6.7 billion yuan, reflecting an 18.09% year-on-year increase, with innovative drugs accounting for 32% of the pharmaceutical segment [3] Group 3: Strategic Collaborations and Future Growth - Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, signed a global exclusive licensing agreement with Pfizer for the oral GLP-1 drug YP05002, with potential total payments exceeding 2 billion dollars [4] - A strategic partnership with Clavis Bio aims to develop innovative therapies based on cutting-edge targets, with potential payments up to 7.25 billion dollars [4] - The innovative drug growth is further supported by the successful global development of core products from Fuhong Hanlin, which saw a stock price increase of approximately 150% in 2025 [4] Group 4: Globalization and Financial Performance - Fosun's overseas business revenue reached a historic high of 53% in the first half of 2025, reflecting its deep industry layout and operations in over 40 countries [6] - The overseas revenue from Fosun Pharma's innovative drugs grew by 184%, surpassing 10 billion yuan [7] - The financial health of Fosun is reinforced by strategic asset divestitures and a reduction in debt costs, with total debt to total capital ratio at 53% as of mid-2025 [8][9]

文旅消费作为复星的核心主业之一，马年春节期间多条产品线展现了出强劲的增长势头。其中，上海豫 园商城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全包"度假 村春节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿元，同比增 长20%，创下历史最佳春节表现。 与此同时，春节期间，复星的创新药赛道也好消息不断。旗下的生物医药研发平台复宏汉霖宣布其研发 的HLX15-SC（重组抗CD38全人单克隆抗体注射液-皮下注射）1期临床试验申请分别获中国国家药监局 批准和美国食品药品管理局（FDA）批准。据了解，HLX15是达雷妥尤单抗生物类似药，目标市场潜 力较大，2024年全球销售额约128.8亿美元。而在2月22日，中国首个自主研发的利妥昔单抗生物类似药 ——汉利康迎来上市七周年，该药曾一举填补了国产CD20单抗的空白，作为复星医药"十年磨一剑"的 成果，其标志着中国生物药研发迈出了从跟随到并跑的关键一步。 创新药等进入密集收获期，创新引擎动力强劲 2025年，复星的创新研发以肉眼可见的速度推进，尤其以创新药为代表，已取得了全球范围内的商业落 地 ...

Core Viewpoint - The Alzheimer's treatment drug, Ganluo Sodium Capsule, is entering a new phase under Fosun Pharma after facing scientific scrutiny and market challenges, with plans for post-marketing confirmatory clinical trials approved by the National Medical Products Administration (NMPA) [1][2]. Group 1: Clinical Development and Market Position - Fosun Pharma has announced a post-marketing confirmatory clinical trial plan for Ganluo Sodium Capsule, with an increased sample size of 1,950 participants, aiming for completion by the end of 2027 and data release in early 2029 [1][2]. - The drug was conditionally approved for marketing in November 2019 and has since benefited hundreds of thousands of patients, with sales exceeding 1 billion yuan since its inclusion in the national medical insurance catalog in 2021 [1][2]. - The price of the drug decreased from 895 yuan to 296 yuan after being included in the national medical insurance catalog, with over 2 million boxes expected to be sold in 2024 alone [1]. Group 2: Scientific and Regulatory Challenges - The drug faced challenges due to the NMPA not approving the extension of its conditional marketing authorization, leading to a supply interruption and various criticisms [2]. - Prior to conditional approval, Ganluo Sodium Capsule completed phase III confirmatory clinical trials with 818 participants across 34 clinical research centers, and real-world studies involving 3,300 participants have been submitted to validate its long-term safety and efficacy [3]. Group 3: Market Demand and Strategic Response - Alzheimer's disease has become a significant public health challenge in China, with nearly 17 million patients reported in 2021, representing 29.8% of global cases [4]. - The existing treatment options are limited and primarily symptomatic, highlighting a substantial unmet clinical need for effective therapies [4][5]. - The Chinese government is encouraging innovation in drug development, aligning with Fosun Pharma's strategic focus on addressing unmet clinical needs in the Alzheimer's treatment space [5]. Group 4: Company Capabilities and Future Outlook - Fosun Pharma's confidence in taking over the Ganluo Sodium project stems from its proven integrated capabilities in research, clinical trials, and commercialization, with ongoing investments in CNS-related products [6]. - The company has successfully launched several innovative drugs in China and is expanding its clinical and commercial teams in the U.S. to support global market entry [6]. - If clinical results are positive, Ganluo Sodium could re-enter the market post-2029, enhancing Fosun Pharma's capabilities in CNS diseases and attracting further collaborations [7].

Core Viewpoint - The core viewpoint of the article emphasizes that Fosun Pharma is focusing on innovation and accelerating globalization through a series of strategic actions in the first half of 2025, despite facing challenges in its core business performance [4][5][11]. Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 195.14 billion yuan, a year-on-year decline of 4.63% [5][6]. - The net profit, excluding non-recurring gains, was 9.61 billion yuan, down 23.39% year-on-year, indicating pressure on core business operations [5][6]. - The increase in net profit by 38.96% to 17.02 billion yuan was primarily due to investment income of 21.2 billion yuan from the sale of non-core assets [5][6]. - The pharmaceutical segment, which accounts for 71.24% of total revenue, saw a revenue decline of 5.29% to 139.01 billion yuan [7][19]. Business Segments - The innovative drug business grew by over 14% year-on-year, reaching over 43 billion yuan, and now represents 31% of the pharmaceutical segment's revenue [7][8]. - The medical health services segment generated 35.92 billion yuan, a slight decrease of 1.83%, affected by price adjustments and centralized procurement policies [7]. - The medical devices and diagnostics segment reported revenue of 19.55 billion yuan, down 5.51%, impacted by geopolitical tensions affecting overseas operations [7]. Strategic Actions - The company has been actively restructuring its strategy, including the sale of non-core assets to focus on core innovative businesses, with over 20 billion yuan in signed disposals in the first half of 2025 [11][19]. - In August 2025, Fosun Pharma launched a new round of equity incentive plans with clear performance targets for net profit and innovative drug revenue growth [17][19]. - The company has made significant international collaborations, including licensing agreements for innovative drugs, indicating a strong push for global expansion [12][20]. Management Changes - In April 2025, Fosun Pharma underwent a significant management reshuffle, appointing new leadership with diverse backgrounds to drive its strategic focus on innovation and internationalization [15][16]. - The new management team is characterized by a strong emphasis on technical expertise and international experience, aiming to enhance the company's operational capabilities [16]. Market Response - The stock performance of Fosun Pharma has shown a divergence between A-shares and H-shares, with A-shares lagging behind the industry average while H-shares have outperformed significantly [9][10]. - Analysts have differing views on the company's future, with some optimistic about its innovative pipeline and others cautious due to ongoing pressures from centralized procurement policies [21].

Core Viewpoint - The company has initiated the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang for the treatment of active glomerulonephritis in mainland China [1][2]. Group 1: Clinical Study Overview - The study is a double-blind, randomized, controlled, multi-center Phase II trial aimed at evaluating the efficacy, safety, and tolerability of HLX79 combined with Hanlikang compared to a placebo in patients with active glomerulonephritis, including lupus nephritis (LN) and membranous nephropathy (MN) [2]. - The study consists of two phases: the first phase is a dose-escalation period where eligible participants will receive HLX79 (10 mg/kg, 20 mg/kg, or 30 mg/kg) combined with either Hanlikang or a Hanlikang placebo (375 mg/m²) weekly [2]. - The second phase is a preliminary efficacy exploration period, where eligible participants will receive HLX79 (high dose/low dose) combined with Hanlikang (375 mg/m²), HLX79 placebo combined with Hanlikang, or HLX79 placebo combined with Hanlikang placebo weekly, with the primary objective of evaluating clinical efficacy [2]. Group 2: Market Context - As of the date of the announcement, there are no similar combination therapies approved for marketing globally [3].

Core Viewpoint - The company Fuhong Hanlin (02696) has announced the completion of the first patient dosing in a Phase II clinical trial for HLX79 injection combined with Hanlikang (Rituximab injection) for the treatment of active glomerulonephritis in China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The study is a double-blind, randomized, controlled, multi-center Phase II clinical trial aimed at evaluating the efficacy, safety, and tolerability of HLX79 combined with Hanlikang compared to placebo in patients with active glomerulonephritis, specifically lupus nephritis (LN) and membranous nephropathy (MN) [2] - The trial consists of two phases: the first phase is a dose-escalation period where eligible participants will receive weekly doses of HLX79 (10 mg/kg, 20 mg/kg, or 30 mg/kg) combined with Hanlikang or Hanlikang placebo (375 mg/m²) [2] - The primary objective of the first phase is to assess the safety and tolerability of HLX79 combined with Hanlikang compared to placebo combined with Hanlikang in treating active glomerulonephritis [2] Group 2 - The second phase is an exploratory efficacy phase where eligible participants will receive weekly doses of HLX79 (high dose/low dose) combined with Hanlikang (375 mg/m²), HLX79 placebo combined with Hanlikang, or HLX79 placebo combined with Hanlikang placebo in a 2:2:1:1 ratio [2] - The primary objective of the second phase is to evaluate the clinical efficacy of HLX79 combined with Hanlikang, placebo combined with Hanlikang, and placebo treatment for active glomerulonephritis on top of standard treatment [2] - Secondary objectives include assessing other clinical efficacy, safety, tolerability, pharmacokinetic characteristics, and immunogenicity, while exploratory objectives aim to evaluate the dynamic changes of potential biomarkers [2] - As of the date of the announcement, there are no similar combination therapies approved for marketing globally [2]

Core Viewpoint - Fosun Pharma has completed its board of directors' re-election and appointed a new senior management team, indicating a strategic shift towards leveraging internal talent with extensive experience in the company [1][2]. Group 1: Board of Directors and Management Changes - Chen Yuqing has been appointed as the Chairman, with Guan Xiaohui as Co-Chairman and Wen Deyong as Vice Chairman [1]. - The new CEO and President, Liu Yi, will take office on June 24, 2025, alongside Co-Presidents Li Jing, Wang Xingli, and Zhang Wenjie [1]. - The majority of the new board members have long tenures within the company, showcasing a preference for internal candidates [1][2]. Group 2: Background of Key Executives - Chen Yuqing joined Fosun Pharma in January 2010 and has held various HR-related positions before becoming Co-CEO in June 2022 [1]. - Guan Xiaohui has been with the company since May 2000, previously serving as CFO and holding various leadership roles [1][2]. - Wen Deyong, who has a pharmacy background, joined Fosun Pharma in May 2002 and has held significant positions within the company [2]. Group 3: New Executive Team Profiles - Zhang Wenjie, newly appointed Executive President, was previously known for his role at Fosun Pharma's innovative drug platform, Fuhong Hanlin, and has experience in international pharmaceutical companies [3]. - Liu Yi, the current CEO, has been with the company since November 2015 and has a background in medical devices and diagnostics [3]. - Other new executives, such as Li Jing and Wang Xingli, bring solid pharmaceutical backgrounds and experience from major pharmaceutical companies [2].

Core Viewpoint - CITIC Securities initiated coverage on Fosun International (00656.HK) with a "Buy" rating, highlighting the company's diversified asset portfolio and robust growth in asset quality, which warrants market attention [1]. Health Sector - Fosun's health sector encompasses pharmaceuticals, medical devices, diagnostics, and healthcare services, with key products including Hanlikang, Hanquyou, Hanshuang, and Yikaida [2]. - Hanlikang is the first domestically produced rituximab approved for treating lymphoma, leukemia, and rheumatoid arthritis; Hanquyou is a trastuzumab approved in over 50 countries for HER2-positive breast and gastric cancer; Hanshuang is the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer in over 30 countries; Yikaida is the first CAR-T product in China for relapsed/refractory large B-cell lymphoma [2]. Leisure Sector - The leisure sector is being optimized with a focus on brand development, particularly through the Oriental aesthetics concept, with Yuyuan Holdings enhancing its financial stability and multi-brand strategy [2]. - Club Med, under Fosun Tourism, achieved record revenue by focusing on high-end all-inclusive offerings, while Atlantis Sanya reached new occupancy highs, maintaining brand competitiveness [2]. Wealth Sector - The asset quality of Fosun's wealth sector is steadily improving, with Fosun Portugal Insurance projected to achieve approximately €6.17 billion in gross premium income in 2024, increasing the international business share from about 5% in 2014 to 29.8% [3]. - Domestic insurance companies, including Fosun P&C and Fosun United Health Insurance, are experiencing significant growth, with Fosun P&C's total premium income expected to rise from RMB 4.35 billion in 2023 to RMB 9.25 billion in 2024, both companies achieving profitability [3]. - The ongoing growth of these companies is expected to lay a solid foundation for the group's future development [3].

Core Viewpoint - CITIC Securities initiated coverage on Fosun International (00656.HK) with a "Buy" rating, highlighting the company's diversified asset portfolio and robust growth in asset quality, which warrants market attention [1] Group 1: Health Sector - Fosun's health sector encompasses pharmaceuticals, medical devices, diagnostics, and healthcare services, with key products including Hanlikang, Hanquyou, Hanshuang, and Yikaida [2] - Hanlikang is the first domestically produced rituximab approved for treating lymphoma, leukemia, and rheumatoid arthritis; Hanquyou is a trastuzumab approved in over 50 countries for HER2-positive breast and gastric cancer; Hanshuang is the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer in over 30 countries; Yikaida is the first CAR-T product in China for relapsed/refractory large B-cell lymphoma [2] Group 2: Happiness Sector - The happiness sector is undergoing brand optimization, with Yuyuan Holdings enhancing its financial stability and multi-brand strategy, including upgrading jewelry stores to create a cohesive brand image [2] - Club Med, under Fosun Tourism, achieved record revenue by focusing on high-end all-inclusive offerings, while Atlantis Sanya reached new occupancy highs, maintaining brand competitiveness [2] Group 3: Wealth Sector - The asset quality of Fosun's wealth sector is steadily improving, with Fosun Portugal Insurance projected to achieve approximately €6.17 billion in gross premium income in 2024, increasing international business share from about 5% in 2014 to 29.8% [3] - Domestic insurance companies, including Fosun's P&C and health insurance, are experiencing significant growth, with Fosun P&C's total premium income expected to rise from RMB 4.35 billion in 2023 to RMB 9.25 billion in 2024, both companies achieving profitability [3] - The ongoing growth of these companies is expected to lay a solid foundation for the group's future development [3]